Developing base-editing medicines that rewrite single letters of DNA, still in clinical trials.
$23.47close as of 2026-10-16
-9.0% over 1Y · 25.8 points behind the S&P 500
BEAMS&P 500 (SPY), rebased to BEAM's first close
“Can Beam submit risto-cel for approval as early as the end of 2026 while advancing BEAM-302 pivotal development?”
Editorial note · updated 2026-10-08
The TenQ Radar
Beam Therapeutics in 36 checks
Beam Therapeutics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 9 of 36 checks passed.
The Beam Therapeutics story
What drives Beam Therapeutics, what its price assumes and what could change the story, written from its own filings.
Approval preparations advance. Beam completed adult and adolescent dosing in the BEACON trial and expects a risto-cel approval application as early as the end of 2026.
Funding includes another draw. Beam’s operating runway into mid-2029 assumes an additional $200 million from Sixth Street alongside $1.2 billion in cash, cash equivalents, and marketable securities at June 30, 2026.
Growth without cash generation. Revenue rose 158.9% to $156 million over the last twelve months, but free cash flow was -$373 million.
Q2 '26 · quarter to 30 June 2026 · reported 4 August 2026 · Earnings release ↗
Revenue$490,000-94%vs 2025-98%vs Q1
Earnings-$123M-$21Mvs 2025-$28Mvs Q1
What the release says
Highlights
Beam dosed the first patient in the global pivotal cohort of the BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD), with the cohort designed to support a potential accelerated approval path in the United States.
Dosing is complete for all adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel for sickle cell disease, and a Biologics License Application (BLA) submission is expected as early as year-end 2026.
The company ended the second quarter of 2026 with $1.2 billion in cash, cash equivalents, and marketable securities, and expects its cash runway to support operations into mid-2029, including anticipated product launches and clinical milestones.
Beam received FDA clearance for the investigational new drug (IND) application for BEAM-304 in phenylketonuria (PKU) and has initiated clinical start-up activities for the planned Phase 1/2 trial.
What management expects
Beam expects its cash, cash equivalents, and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from its facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029.
The company anticipates reporting updated clinical data for BEAM-302 at the European Respiratory Society Congress in September 2026, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel by year-end 2026.
Key risks
New The Chief Executive Officer adopted a Rule 10b5-1 trading arrangement for the sale of company securities on June 16, 2026, which is scheduled to last until June 30, 2027, or until all transactions are completed or expire without execution.
Beam has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future, which could impair its ability to raise capital, maintain research and development efforts, expand its business, or continue operations.
The company will need substantial additional funding to support its research, development, and commercialization activities, and if it cannot raise capital when needed, it may be forced to delay, reduce, or eliminate programs or commercialization efforts.
Beam's product candidates are early in development and may never achieve regulatory approval or commercial success, and the company has not yet completed any pivotal clinical trials or generated revenue from product sales.
Base editing is a novel technology with limited clinical validation, and there are significant risks related to safety, efficacy, delivery, and potential off-target effects, which could delay or prevent regulatory approval or limit commercial potential.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Beam Therapeutics reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●1/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
15.5xown 6-year median 59.5x
-15.4%cash earned per $ of price
-whole-business multiple
Valuation history
Is BEAM's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2026
-
15.536
2.271
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 15.5x sales, the market is paying 74% less than BEAM's own 6-year median of 59.5x. Pessimism is priced in - the question is whether it is deserved.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is BEAM's free cash flow yield at today's price?
Period
FCF yield
2020
-0.0794
2021
-0.0195
2022
-0.0073
2023
-0.0769
2024
-0.1619
2025
-0.1638
2026
-0.1538
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys -15.4% of annual free cash flow, more than its 6-year median of -7.7% - the cash is cheaper than usual.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●4/6
Growing, with caveats: revenue +158.9% over the last year.
+158.9%vs the year before
+31.9%compound annual
-net income growth
-compound annual
Revenue history
Is BEAM's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q2 2019
6,000
Q3 2019
6,000
Q1 2020
6,000
Q2 2020
6,000
Q3 2020
6,000
Q4 2020
6,000
Q1 2021
6,000
Q2 2021
6,000
Q3 2021
763,000
Q4 2021
51.1M
Q1 2022
8.4M
Q2 2022
16.7M
Q3 2022
15.8M
Q4 2022
20.0M
Q1 2023
24.2M
Q2 2023
20.1M
Q3 2023
17.2M
Q4 2023
316.2M
Q1 2024
7.4M
Q2 2024
11.8M
Q3 2024
14.3M
Q4 2024
30.1M
Q1 2025
7.5M
Q2 2025
8.5M
Q3 2025
9.7M
Q4 2025
114.1M
Q1 2026
31.7M
Q2 2026
490,000
2019
18,000
2020
24,000
2021
51.8M
2022
60.9M
2023
377.7M
2024
63.5M
2025
139.7M
→Revenue reached $140M in 2025, compounding +32% a year since 2022 though the path has been bumpy. The trailing twelve months are already running at $156M, ahead of the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Profit history
Is BEAM's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q1 2019
-13.6M
Q2 2019
-17.9M
Q3 2019
-19.0M
Q4 2019
-27.9M
Q1 2020
-30.5M
Q2 2020
-34.2M
Q3 2020
-34.5M
Q4 2020
-95.5M
Q1 2021
-201.6M
Q2 2021
-76.3M
Q3 2021
-28.1M
Q4 2021
-64.7M
Q1 2022
-69.2M
Q2 2022
-72.0M
Q3 2022
-109.6M
Q4 2022
-38.3M
Q1 2023
-96.5M
Q2 2023
-82.8M
Q3 2023
-96.1M
Q4 2023
142.8M
Q1 2024
-98.7M
Q2 2024
-91.1M
Q3 2024
-96.7M
Q4 2024
-90.4M
Q1 2025
-108.3M
Q2 2025
-102.1M
Q3 2025
-112.7M
Q4 2025
243.2M
Q1 2026
-94.3M
Q2 2026
-122.7M
2019
-78.3M
2020
-194.6M
2021
-370.6M
2022
-289.1M
2023
-132.5M
2024
-376.7M
2025
-80.0M
→The company lost $80M in 2025, less than the $377M it lost the year before. The losses are narrowing, but it is still burning shareholder money.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are BEAM's revenue and earnings growing?
Year
Revenue growth
Earnings growth
2,020
0.3333
-
2,021
2,159
-
2,022
0.1751
-
2,023
5.2001
-
2,024
-0.8318
-
2,025
1.2001
-
2026
1.5888
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue grew 159% over the twelve months to 2026-06-30, against an average of +43298% a year over 2021-2025.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are BEAM's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,019
0.0028
-13.0442
2,020
0.0005
-2.3987
2,021
0.8072
-1.7606
2,022
0.8701
-0.3774
2,023
4.8957
-2.371
2,024
0.7717
-4.3273
2,025
1.4129
-3.6403
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $1.41 in 2025, compounding +18% a year against +32% for BEAM as a whole. Dilution absorbed about 14.3 points of that growth. The trailing twelve months are running at $1.58 a share. Free cash flow per share stands at $-3.64.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
-kept after direct costs
-242.3%kept after running costs
-7.9%profit on shareholders' money
-29.0%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does BEAM keep on each sale?
Year
Gross
Operating
Net
2,019
-
-4,175
-4,351
2,020
-
-5,532
-8,108
2,021
-
-7.5701
-7.1491
2,022
-
-5.5561
-4.7454
2,023
-
-0.4673
-0.3509
2,024
-
-6.5425
-5.9313
2,025
-
-2.7457
-0.5724
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin widened 281 points to -275% since 2022. The bottom line is still negative: costs below the operating line eat what is left. BEAM doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does BEAM's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,019
-72.0M
-78.3M
2,020
-95.7M
-194.6M
2,021
-66.3M
-370.6M
2,022
22.5M
-289.1M
2,023
-149.2M
-132.5M
2,024
-347.2M
-376.7M
2,025
-345.1M
-80.0M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$345M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does BEAM earn?
Year
ROE
ROA
ROCE
2,021
-0.6913
-0.2514
-0.3112
2,022
-0.3706
-0.2155
-0.3027
2,023
-0.1546
-0.0908
-0.1407
2,024
-0.4394
-0.3413
-0.4508
2,025
-0.0811
-0.054
-0.2772
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of -8% and ROCE of -29% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Cash conversion
How much of each sale does BEAM turn into free cash flow?
Period
FCF margin
2019
-4,696
2020
-4,671
2021
-2.1811
2022
-0.4337
2023
-0.4843
2024
-5.6077
2025
-2.5765
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does BEAM spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,019
695.4444
3,034
390.4444
2,020
681.5417
4,299
640.8333
2,021
0.9029
7.4664
0.8404
2,022
0.8035
5.1148
1.3841
2,023
0.0893
1.158
0.2612
2,024
0.1408
5.7867
1.8997
2,025
0.107
2.9312
0.6744
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 293% of revenue (stock compensation 67%, capital spending 11%). That share has fallen since 2022, so the cost of competing is easing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Return on capital employed
Is BEAM's return on capital above what its capital costs?
Period
Return on capital employed
2019
-0.5919
2020
-0.38
2021
-0.3112
2022
-0.3027
2023
-0.1407
2024
-0.4508
2025
-0.2772
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→BEAM's return on capital is negative at -27.7% in 2025. The capital in the business is not yet earning anything back.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow -$359M on a net loss of $87M
IV
Financial health
●●●●●●3/6
Financially sound overall, with one or two things worth watching.
0.09xborrowed vs owned
14.6xnear-term bills coverage
-147xearnings ÷ interest bill
$1.2Bcash plus short-term investments
Debt & cash
How much debt does BEAM carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,018
-
147.9M
2,019
-
37.2M
2,020
-
299.7M
2,021
0
881.4M
2,022
0
1.08B
2,023
0
1.19B
2,024
0
850.7M
2,025
0
1.25B
2,026
100.3M
1.15B
◌ each quarterly point is the balance sheet at that quarter end
→The company holds $1.2B in cash against $100M of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do BEAM's current assets cover the bills due within a year?
Period
Current ratio
2019
3.2447
2020
3.0128
2021
5.9644
2022
4.8878
2023
5.8913
2024
4.8232
2025
13.088
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 14.6x of current assets for every dollar due within the year. That is stronger than in 2019.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of BEAM's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2019
-4,000
2020
-3,989
2021
-1.2782
2022
0.3698
2023
-0.395
2024
-5.4669
2025
-2.4695
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→BEAM's operations consumed cash rather than produced it over the last twelve months. Up from -400016.7% in 2019.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is BEAM's shareholder equity (book value) growing?
Period
Equity ($)
2018
-117.4M
2019
-201.1M
2020
245.6M
2021
826.7M
2022
733.5M
2023
981.3M
2024
733.5M
2025
1.24B
2026
1.07B
→The company's own capital grew from $981M in 2023 to $1.1B (+9%). The business is building book value rather than consuming it.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
BEAM returns nothing to shareholders yet, and the share count keeps rising. Every dollar stays in the business.
-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$82Mlast 12m, dilutes the buybacks
+1490.2%since 2019 (split-adjusted)
Share count change (split-adjusted)
Is BEAM's share count rising or falling?
Year
Share-count change
2,020
6.2124
2,021
0.3743
2,022
0.0901
2,023
0.1019
2,024
0.0669
2,025
0.2016
→The share count grew 20.2% in 2025, averaging 12.3% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has BEAM's revenue per share grown faster than its share count?
Change since 2019. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2019
Revenue per share, change since 2019
2,019
0
0
2,020
6.2124
-0.8151
2,021
8.9123
289.5704
2,022
9.8055
312.2146
2,023
10.9069
1,761
2,024
11.7034
276.7816
2,025
14.2642
507.6094
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→BEAM issued 1426% more shares from 2019 to 2025, but revenue per share still rose 50761%. The dilution bought more growth than it cost existing holders.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→BEAM is in a downtrend: the price is below the cloud where recent trading settled and that cloud is still falling. The last two weeks have ticked up, but the price is still below its level a month ago, so it is early.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are BEAM's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
0
305,000
2023-12
0
0
2024-01
0
1.6M
2024-02
0
27.5M
2024-03
0
2.0M
2024-04
0
1.7M
2024-05
0
0
2024-06
0
1.5M
2024-07
0
29,094
2024-08
0
0
2024-09
0
1.5M
2024-10
0
1.4M
2024-11
0
1.3M
2024-12
0
0
2025-01
0
860,679
2025-02
0
560,045
2025-03
0
0
2025-04
0
1.4M
2025-05
0
0
2025-06
0
0
2025-07
0
1.0M
2025-08
0
0
2025-09
0
0
2025-10
0
1.3M
2025-11
0
0
2025-12
0
204,551
2026-01
0
2.4M
2026-02
0
1.1M
2026-03
0
1.1M
2026-04
0
1.4M
2026-05
0
0
2026-06
0
11.8M
2026-07
0
429,037
2026-08
0
0
2026-09
0
0
2026-10
0
1.2M
→Since November 2023, insiders sold $64M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 47 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-10-16
John M. Evans
CEO
exercise
25,000
$1.03
$25,750
2026-10-16
John M. Evans
CEO
SELL
25,000
$23.98
$599,595
2026-10-15
John M. Evans
CEO
exercise
25,000
$1.03
$25,750
2026-10-15
John M. Evans
CEO
SELL
25,000
$23.57
$589,150
2026-10-01
Bethany J Cavanagh
SVP, Finance and Treasurer
SELL
187
$24.41
$4,565
2026-07-27
Amy Simon
Chief Medical Officer
SELL
16,667
$25.74
$429,037
2026-06-30
Amy Simon
Chief Medical Officer
SELL
373
$34.73
$12,954
2026-06-30
John M. Evans
CEO
exercise
25,000
$1.03
$25,750
2026-06-30
John M. Evans
CEO
SELL
23,100
$34.26
$791,482
2026-06-30
John M. Evans
CEO
SELL
1,900
$34.84
$66,203
2026-06-29
John M. Evans
CEO
exercise
18,663
$0.67
$12,504
2026-06-29
John M. Evans
CEO
exercise
6,337
$1.03
$6,527
2026-06-29
John M. Evans
CEO
SELL
13,421
$35.13
$471,528
2026-06-29
John M. Evans
CEO
SELL
11,579
$35.91
$415,824
2026-06-26
Fmr LLC
10% owner
SELL
251,488
$35.26
$8.87M
2026-06-25
Fmr LLC
10% owner
SELL
33,372
$35.12
$1.17M
2026-06-17
Giuseppe Ciaramella
President
exercise
6,505
$0.67
$4,358
2026-06-17
Giuseppe Ciaramella
President
exercise
29,000
$1.03
$29,870
2026-04-01
John M. Evans
CEO
SELL
30,078
$24.58
$739,317
2026-04-01
Amy Simon
Chief Medical Officer
SELL
6,700
$24.58
$164,686
2026-04-01
Bethany J Cavanagh
SVP, Finance and Treasurer
SELL
3,242
$24.58
$79,688
2026-04-01
Christine Bellon
Chief Legal Officer
SELL
5,956
$24.58
$146,398
2026-04-01
Giuseppe Ciaramella
President
SELL
11,810
$24.58
$290,290
2026-03-31
John M. Evans
CEO
exercise
25,000
$0.67
$16,750
2026-03-31
John M. Evans
CEO
SELL
25,000
$22.76
$569,085
2026-03-30
John M. Evans
CEO
exercise
25,000
$0.67
$16,750
2026-03-30
John M. Evans
CEO
SELL
25,000
$22.37
$559,230
2026-02-24
Giuseppe Ciaramella
President
exercise
35,000
$17.00
$595,000
2026-02-24
Giuseppe Ciaramella
President
SELL
35,000
$32.00
$1.12M
2026-01-30
John M. Evans
CEO
exercise
25,000
$0.67
$16,750
2026-01-30
John M. Evans
CEO
SELL
22,094
$28.27
$624,672
2026-01-30
John M. Evans
CEO
SELL
2,906
$29.00
$84,274
2026-01-29
John M. Evans
CEO
exercise
19,336
$0.67
$12,955
2026-01-29
John M. Evans
CEO
exercise
5,664
$0.67
$3,795
2026-01-29
John M. Evans
CEO
SELL
16,333
$29.19
$476,801
2026-01-29
John M. Evans
CEO
SELL
8,667
$29.74
$257,781
2026-01-22
Bethany J Cavanagh
SVP, Finance and Treasurer
SELL
6,198
$35.00
$216,933
2026-01-22
Christine Bellon
Chief Legal Officer
SELL
1,371
$34.00
$46,614
2026-01-20
Bethany J Cavanagh
SVP, Finance and Treasurer
SELL
3,034
$30.12
$91,384
2026-01-15
Christine Bellon
Chief Legal Officer
SELL
2,111
$33.62
$70,976
2026-01-15
Christine Bellon
Chief Legal Officer
SELL
15,959
$34.72
$554,068
2026-01-15
Christine Bellon
Chief Legal Officer
SELL
559
$35.40
$19,788
2025-12-31
Sravan Kumar Emany
Chief Financial Officer
SELL
6,294
$27.10
$170,567
2025-12-31
Christine Bellon
Chief Legal Officer
SELL
1,254
$27.10
$33,983
2025-10-27
Fmr LLC
10% owner
SELL
459
$26.68
$12,246
2025-10-02
John M. Evans
CEO
exercise
25,000
$0.67
$16,750
2025-10-02
John M. Evans
CEO
SELL
25,000
$24.63
$615,668
2025-10-01
Bethany J Cavanagh
SVP, Finance and Treasurer
SELL
467
$24.53
$11,456
2025-10-01
Christine Bellon
Chief Legal Officer
SELL
373
$24.53
$9,150
2025-10-01
John M. Evans
CEO
exercise
25,000
$0.67
$16,750
2025-10-01
John M. Evans
CEO
SELL
25,000
$24.51
$612,655
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
105.9%on Form 13F, 30 June 2026
1.8%officers, directors, founders
74.3%together
2of the 18 TenQ follows
Top holders
Who owns Beam Therapeutics stock?
Fund managers filing Form 13F held 105.9% of the company's shares on 30 June 2026. The largest holder is FMR LLC, with 12.2%. Insiders hold 1.8%.
#
Holder
Stake
Shares
Value
Change
1
FMR LLCFund manager
12.21%
12.6M
$296M
+1.3%
2
Farallon Capital Management, L.l.c.Fund manager
9.91%
10.2M
$240M
+1.0%
3
ARK Investment Management LLCFund manager
9.91%
10.2M
$240M
-15.7%
4
Dapice Joshua J.Holds over 5% · Form 13G, 31 December 2025
9.82%
10.1M
$238M
-
5
BlackRock, Inc.Fund manager
8.71%
9.0M
$211M
+6.0%
6
State Street CorpFund manager
5.64%
5.8M
$137M
+2.2%
7
Vanguard Portfolio Management LLCFund manager
4.76%
4.9M
$116M
+7.7%
8
Robert NelsenHolds over 5% · Form 13G, 31 March 2025
4.45%
4.6M
$108M
-
9
Vanguard Capital Management LLCFund manager
4.45%
4.6M
$108M
+5.1%
10
ARCH Venture Management, LLCFund manager
4.40%
4.5M
$107M
+0.0%
11
Amova Asset Management Americas, Inc. and Sumitomo Mitsui Trust Group, Inc.Fund manager
3.35%
3.5M
$81M
-9.7%
12
Price T Rowe Associates IncFund manager
3.31%
3.4M
$80M
+25.9%
13
Kynam Capital Management, LPFund manager
2.75%
2.8M
$67M
-22.9%
14
Geode Capital Management, LLCFund manager
2.51%
2.6M
$61M
+7.4%
15
Dimensional Fund Advisors LPFund manager
2.15%
2.2M
$52M
+3.3%
16
Morgan StanleyFund manager
1.89%
2.0M
$46M
+201.0%
17
Contrarius Group Holdings LtdFund manager
1.56%
1.6M
$38M
+202.7%
18
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCFund manager
1.50%
1.6M
$36M
-6.2%
19
Two Sigma Investments, LPFund manager
1.34%
1.4M
$33M
+14.6%
20
Casdin Capital, LLCFund manager
1.31%
1.4M
$32M
+0.0%
The full list of top holders is free with an account
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Super investors
Which super investors own Beam Therapeutics stock?
Cathie Wood's ARK Investment Management holds Beam Therapeutics, 2.3% of its portfolio, as of 30 June 2026. 2 of the 18 super investors TenQ follows hold it.
Cathie Wood's ARK Investment Management reported a stake of 9.95% of the company, filed 14 August 2026 (Schedule 13G).
Source: each firm's Form 13F for the quarter to 30 June 2026, and its Form 4 and Schedules 13D and 13G since. A weight is the holding's share of the firm's 13F portfolio. All super investors
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.